Ambiguity-Free Method for Fast and Precise GNSS Differential Positioning

Methods based on integer ambiguity determination, such as the least-squares ambiguity decorrelation adjustment (LAMBDA) method, are currently used for precise global navigation satellite system (GNSS) differential positioning. In the present paper, the author proposes an ambiguity-free method based on a dedicated mixed (stochastic/deterministic) optimization algorithm that, unlike the LAMBDA method, is capable of providing reliable and accurate results using few observation epochs (e.g., 1-cm accuracy with just two epochs), having the additional advantages of insensitivity to cycle slips and impossibility of wrong ambiguity fixation. In addition, it is demonstrated that the application of the linear (deterministic) part of this algorithm yields the correct baseline results much more easily and quickly than methods requiring integer ambiguity determination, provided the initial approximate coordinates are accurate to a few centimeters. However, the use of ambiguity-free methods requires that the integer character of the ambiguities be preserved so that they can be eliminated; therefore no ionosphere-free combination can be computed and the methods are valid only for short baselines (e.g., less than 10 km).Baselga Moreno, S. (2014). Ambiguity-Free Method for Fast and Precise GNSS Differential Positioning. Journal of Surveying Engineering. 140(1):22-27. doi:10.1061/(ASCE)SU.1943-5428.0000111S2227140

TESS unveils the phase curve of WASP-33b. Characterization of the planetary atmosphere and the pulsations from the star

We present the detection and characterization of the full-orbit phase curve and secondary eclipse of the ultra-hot Jupiter WASP-33b at optical wavelengths, along with the pulsation spectrum of the host star. We analyzed data collected by the Transiting Exoplanet Survey Satellite (TESS) in sector 18. WASP-33b belongs to a very short list of highly irradiated exoplanets that were discovered from the ground and were later visited by TESS. The host star of WASP-33b is of delta Scuti-type and shows nonradial pulsations in the millimagnitude regime, with periods comparable to the period of the primary transit. These completely deform the photometric light curve, which hinders our interpretations. By carrying out a detailed determination of the pulsation spectrum of the host star, we find 29 pulsation frequencies with a signal-to-noise ratio higher than 4. After cleaning the light curve from the stellar pulsations, we confidently report a secondary eclipse depth of 305.8 +/- 35.5 parts-per-million (ppm), along with an amplitude of the phase curve of 100.4 +/- 13.1 ppm and a corresponding westward offset between the region of maximum brightness and the substellar point of 28.7 +/- 7.1 degrees, making WASP-33b one of the few planets with such an offset found so far. Our derived Bond albedo, A_B = 0.369 +/- 0.050, and heat recirculation efficiency, epsilon = 0.189 +/- 0.014, confirm again that he behavior of WASP-33b is similar to that of other hot Jupiters, despite the high irradiation received from its host star. By connecting the amplitude of the phase curve to the primary transit and depths of the secondary eclipse, we determine that the day- and nightside brightness temperatures of WASP-33b are 3014 +/- 60 K and 1605 +/- 45 K, respectively. From the detection of photometric variations due to gravitational interactions, we estimate a planet mass of M_P = 2.81 +/- 0.53 M$_J.Comment: 19 pages, 15 figure

Chiral Molecular Tweezers: Synthesis and Reactivity in Asymmetric Hydrogenation

We report the synthesis and reactivity of a chiral aminoborane displaying both rapid and reversible H-2 activation. The catalyst shows exceptional reactivity in asymmetric hydrogenation of enamines and unhindered imines with stereoselectivities of up to 99% ee. DFT analysis of the reaction mechanism pointed to the importance of both repulsive steric and stabilizing intermolecular non-covalent forces in the stereodetermining hydride transfer step of the catalytic cycle

Use of prescription drugs and future delinquency among adolescent offenders

Non-medical use of prescription drugs (NMUPD) by adolescents is a significant public health concern. The present study investigated the profile of NMUPD in 1349 adolescent offenders from the Pathways to Desistance project, and whether NMUPD predicted future delinquency using longitudinal data. Results indicated that increased frequency and recency of NMUPD in adolescent offenders are related to some demographic factors, as well as increased risk for violence exposure, mental health diagnoses, other drug use, and previous delinquency, suggesting that severity of NMUPD is important to consider. However, ANCOVA analyses found that NMUPD was not a significant predictor of drug-related, non-aggressive, or aggressive delinquency 12 months later beyond other known correlates of delinquency. Age, sex, exposure to violence, lower socioeconomic status, more alcohol use, and having delinquency histories were more important than NMUPD in predicting future delinquency. These findings suggest that although NMUPD is an important risk factor relating to many correlates of delinquency, it does not predict future delinquency beyond other known risk factors

An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method

Prostate cancer (PC) is a common cancer among men, and preventive strategies are warranted. Benzoxazinoids (BXs) in rye have shown potential against PC in vitro but human studies are lacking. The aim was to establish a quantitative method for analysis of BXs and investigate their plasma levels after a whole grain/bran rye vs refined wheat intervention, as well as exploring their association with PSA, in men with PC. A quantitative method for analysis of 22 BXs, including novel metabolites identified by mass spectrometry and NMR, was established, and applied to plasma samples from a randomized crossover study where patients with indolent PC (n = 17) consumed 485 g whole grain rye/rye bran or fiber supplemented refined wheat daily for 6 wk. Most BXs were significantly higher in plasma after rye (0.3-19.4 nmol/L in plasma) vs. refined wheat (0.05-2.9 nmol/L) intake. HBOA-glc, 2-HHPAA, HBOA-glcA, 2-HPAA-glcA were inversely correlated to PSA in plasma (p < 0.04). To conclude, BXs in plasma, including metabolites not previously analyzed, were quantified. BX metabolites were significantly higher after rye vs refined wheat consumption. Four BX-related metabolites were inversely associated with PSA, which merits further investigation

Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome:A Feasibility Study

Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as part of the IBD manifestation and to compare the severity of IBS symptoms and pain, bloating and quality of life (QoL). Methods: An eight-week randomised open-label FODMAP elimination with double-blinded, crossover provocations of FODMAP and placebo. Diet patients were on a low-FODMAP diet for eight weeks with blinded two-week provocations after two and six weeks. Questionnaires, blood and stool samples were collected. Results: Patient enrolment was challenging. Nineteen participants were included in the study. Eliminating low FODMAP for two weeks resulted in significant decreases in pain and bloating scores (p 0.05). Conclusions: The results document the possibility of performing a randomised controlled study following the gold standard for testing food intolerance with blinding of the Low FODMAP diet. Recruitment of participants was challenging

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

<p>Abstract</p> <p>Background</p> <p>Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with self-injection and could, therefore, improve treatment adherence. This study was performed to assess the suitability of a new electronic device for the subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS.</p> <p>Methods</p> <p>In this Phase IIIb, multicentre, single-arm study, patients with relapsing MS who had been consistently self-injecting sc IFN beta-1a using an autoinjector for at least 6 weeks were taught to use the new device and self-administered treatment for 12 weeks thereafter. Patient-rated suitability of the device was assessed at the end of Week 12 using the Patient User Trial Questionnaire. Patient satisfaction with, and evaluation of, the injection process was assessed using the MS Treatment Concern Questionnaire. Trainers evaluated the device using the Trainer User Trial Questionnaire.</p> <p>Results</p> <p>At Week 12, 71.6% (73/102) of patients considered the device 'very suitable' or 'suitable' for self-injection; 92.2% (94/102) reported some degree of suitability and only 7.8% (8/102) found the device 'not at all suitable'. At Weeks 4, 8 and 12, most patients reported that injection preparation and clean-up, performing injections and ease of device use in the previous 4 weeks compared favourably with, or was equivalent to, their previous experience of self-injection. Injection-related pain, injection reactions and 'flu-like' symptoms remained stable over the 12 weeks. Each device feature was rated 'very useful' or 'useful' by at least 80% of patients. All trainers and 95.2% (99/104) of patients found device functions 'very easy' or 'easy' to use. Overall convenience was considered the most important benefit of the device.</p> <p>Conclusions</p> <p>Most patients considered the new electronic injection device suitable for the sc injection of IFN beta-1a. They found the device easy to use with useful features, and reported benefits such as overall convenience. The device may, therefore, increase treatment adherence in patients with MS, particularly those with injection-related issues.</p> <p>Trial registration</p> <p>NCT00735007</p